Top 5 stocks in focus on August 13: HDFC Bank, PVR to Cipla; here are the 5 newsmakers of the day

Domestic equity market on Friday, August 10, 2018, closed in red after reflecting bearish sentiments. The escalating trade war tensions between the US and China has spooked investors across the globe, including India. Certain stocks came in the news after the markets were closed on Friday and these can have an impact on the market today, August 13, 2018. Here is the list of five such stocks: 

HDFC Bank: The bank's Deputy Managing Director Paresh Sukthankar has resigned after serving the firm for 24 years. Sukthankar, touted to be the natural successor to Aditya Puri, HDFC bank's CEO and Managing Director, abruptly resigned on Friday from the largest private bank in the country and his shock exit is likely to nudge the bank's board to hasten its hunt for managing director Puri's successor who turns 70 in October 2020 and has to retire at that age, according to RBI norms. 

PVR Ltd.: The multiplex chain PVR has announced that it will buy  South India-based SPI Cinemas Private Ltd. SPI, which is south India’s largest cinema chain and has a presence in the key markets of Tamil Nadu, Telangana, Andhra Pradesh, Karnataka, Kerala, and Mumbai. As per the terms of the proposal, PVR would buy 2,22,7711 equity shares or 71.7% stake in SPI Cinemas from existing shareholders for a total consideration of Rs 633 crore. 

Ashok Leyland: The commercial automobile company has said that its subsidiary Optare Plc has bagged an order from Transport for London (TfL) for 31 electric double-decker buses.

Watch this Zee Business video here:

State Bank of India (SBI): The public sector lender has decided to sell two non-performing assets (NPAs) worth about Rs 2,490 crore and has invited bids from them. The two accounts that will put on the sale are Bombay Rayon Fashions and  Shivam Dhatu Udyog Pvt Ltd and the two firms owe Rs 2,260.79 crore and Rs 229,32 crore to the bank respectively. 

Cipla: The Pharmaceutical company has said that its subsidiary, Cipla USA, Inc, has received final approval from Hyderabad-based MSN Laboratories to market and distribute colon cancer treatment drug Capecitabine in the US market. The company will be marketing the drug in strengths of 150 and 500 mg tablets.